share_log

CareMax Analyst Ratings

CareMaxのアナリスト評価

Benzinga ·  2023/11/17 04:59
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
11/17/2023 6.3% UBS $5 → $1 Downgrades Buy → Neutral
11/10/2023 112.61% Piper Sandler → $2 Downgrades Overweight → Neutral
01/06/2023 537.82% UBS $10 → $6 Maintains Buy
09/07/2022 697.28% Truist Securities → $7.5 Initiates Coverage On → Hold
10/20/2021 1494.56% Jefferies → $15 Initiates Coverage On → Buy
09/13/2021 Piper Sandler Upgrades Neutral → Overweight
09/10/2021 1388.25% Cowen & Co. → $14 Initiates Coverage On → Outperform
07/01/2021 1388.25% Piper Sandler → $14 Initiates Coverage On → Neutral

What is the target price for CareMax (CMAX)?

The latest price target for CareMax (NASDAQ: CMAX) was reported by UBS on November 17, 2023. The analyst firm set a price target for $1.00 expecting CMAX to rise to within 12 months (a possible 6.30% upside). 3 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for CareMax (CMAX)?

The latest analyst rating for CareMax (NASDAQ: CMAX) was provided by UBS, and CareMax downgraded their neutral rating.

When is the next analyst rating going to be posted or updated for CareMax (CMAX)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of CareMax, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for CareMax was filed on November 17, 2023 so you should expect the next rating to be made available sometime around November 17, 2024.

Is the Analyst Rating CareMax (CMAX) correct?

While ratings are subjective and will change, the latest CareMax (CMAX) rating was a downgraded with a price target of $5.00 to $1.00. The current price CareMax (CMAX) is trading at is $0.94, which is out of the analyst's predicted range.

これらの内容は、情報提供及び投資家教育のためのものであり、いかなる個別株や投資方法を推奨するものではありません。 更に詳しい情報
    コメントする